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Reticuloendothelial systemWe have previously shown that the PEGylated LPD (liposome-polycation-DNA) nanoparticles were highly
efﬁcient in delivering siRNA to the tumorwith low liver uptake. Itsmechanism of evading the reticuloendothelial
system (RES) is reported here. In LPD, nucleic acids were condensed with protamine into a compact core, which
was then coated by two cationic lipid bilayers with the inner bilayer stabilized by charge–charge interaction (also
called the supported bilayer). Finally, a detergent-like molecule, polyethylene glycol (PEG)-phospholipid is post-
inserted into the lipid bilayer to modify the surface of LPD. The dynamic light scattering (DLS) data showed that
LPD had improved stability compared to cationic liposomes after incubation with a high concentration of DSPE-
PEG2000, which is known to disrupt the bilayer. LPD prepared with a multivalent cationic lipid, DSGLA, had
enhanced stability compared to those containing DOTAP, a monovalent cationic lipid, suggesting that stronger
charge–charge interaction in the supported bilayer contributed to a higher stability. Distinct nanoparticle
structurewas found in the PEGylatedLPDby transmissionelectronmicroscopy,while the cationic liposomeswere
transformed into tubular micelles. Size exclusion chromatography data showed that approximately 60% of the
total cationic lipids, which were located in the outer bilayer of LPD, were stripped off during the PEGylation; and
about 20% of the input DSPE-PEG2000 was incorporated into the inner bilayer with about 10.6 mol% of DSPE-
PEG2000 presented on the particle surface. This led to complete charge shielding, low liver sinusoidal uptake, and
32.5% injected dose delivered to the NCI-H460 tumor in a xenograft model.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Prolongation of the circulation half-life by surface incorporation of
polyethylene glycol (PEG) in liposomes was demonstrated by us [1]
and others [2] in early 1990s. Macrophages in the reticuloendothelial
system (RES) located in the liver and the spleen vividly take up
particles bound with serum proteins; and surface modiﬁcation by PEG
reduces the opsonization of liposomes andminimizes the clearance by
the RES, leading to improved pharmacokinetic properties. This
approach has been used in a variety of nanoparticle systems to
improve the circulation half-life and enhance the drug delivery. There
are two methods for surface PEGylation of liposomes. The ﬁrst is toynamic light scattering; DSPE-
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ll rights reserved.hydrate a lipid ﬁlm consisting of PEG-phospholipids and other lipid
components, and this self-assembling process allows PEG to extend
from the lipid bilayer to both the inner aqueous core and the outer
aqueous phase. The second method, post-insertion, is also commonly
used inwhich PEG-phospholipids are incubated, usually at an elevated
temperature, with pre-formed liposomes [3]. The PEG conjugates are
inserted into the liposome bilayer due to hydrophobic interaction of
the acyl chains of the conjugates with the liposomal lipids. This
method permits that only the outer surface of liposomes is modiﬁed
with PEG. However, due to the detergent-like activity of the PEG-
phospholipids, the degree of surface PEGylation is usually less than
5 mol% if the liposome integrity is to be preserved [3,4].
LPD (liposome-polycation-DNA) nanoparticle was developed earlier
in our lab [5] and has been used for the delivery of peptide [6] and
nucleic acid, including plasmid DNA [5], oligonucleotide and siRNA [7–
10]. LPD was prepared by mixing cationic liposomes, protamine and
nucleic acids at a ﬁxed ratio. The self-assembled nanoparticles were
100–150 nm in diameter. Recently, we havemodiﬁed LPD nanoparticles
with a high level, i.e., 10 mol%, of PEG-phospholipid conjugate and
showed that the i.v. injected nanoparticles accumulated in the NCI-
H460 human lung tumor at approximately ∼60% injected dose (ID)/g
tissue in a xenograft model [7]. More importantly, liver and spleen
uptakes of the nanoparticles were unusually low. Such RES evasion
property of the nanoparticles is obviously interesting and important for
drug and gene delivery. We have decided to study the mechanism in
some detail.
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TEM (transmission electron microscopy) (Fig. 1A) [11], showing that
the nucleic acid was complexed by protamine to form a compact core,
which was coated with two cationic lipid bilayers (Fig. 1B). The
formation mechanism of the LPD has been proposed (Fig. 1C) [11].
First, the polycation interacts with the nucleic acid to form a
negatively charged compact core. The subsequently added cationic
liposomes collapse onto the core by charge–charge interaction. Finally,
two separate lipid bilayermembranes appear on the surface of the LPD
nanoparticles as the result of bilayer fusion and re-organization. In
this model, the inner bilayer is directly in contact with the core and is
supported and stabilized by the charge–charge interaction of the
cationic lipids with the negatively charged core. We hypothesized that
a supported bilayer can tolerate a high level of DSPE-PEG2000, which is
a detergent-like surfactant, better than a regular bilayer. This unique
feature of LPD may provide an opportunity to modify the formulation
with a high amount of DSPE-PEG2000 to achieve an enhanced surface
shielding and thus improve the pharmacokinetic properties of the
nanoparticle formulation.
In this study, we evaluated the tolerance of liposomes and LPD
to DSPE-PEG2000 micelles by using dynamic light scattering (DLS)
and TEM. We also titrated the input amount of DSPE-PEG2000
micelles for the post-insertion and monitored the stability of the
resulting nanoparticles. Size exclusion chromatography was per-
formed to purify and characterize the PEGylated LPD. The surface
shielding effect of the PEGylated LPD was assessed by measuring
the zeta potential and the non-speciﬁc uptake by the liver
sinusoidal cells in the isolated liver perfusion model. Finally, the
tissue distribution of the PEGylated LPD was studied in a tumor-
bearing mouse model.Fig. 1. Illustration of the structure and formation of LPD. Cryo-TEM photograph (A), the i
formation of the LPD nanoparticles (C). Panel A was reproduced from Tan et al. with permi2. Materials and methods
2.1. Materials
DOTAP, NBD-DOTAP, NBD-PE, cholesterol, DSPE-PEG2000, and
DSPE-PEG2000-CF were purchased from Avanti Polar Lipids, Inc.
(Alabaster, AL). Protamine sulfate (fraction X from salmon sperm),
calf thymus DNA (for hybridization, phenol-chloroform extracted and
ethanol precipitated), and Sepharose CL 2B were from Sigma-Aldrich
(St. Louis, MO). DSGLA was synthesized in our lab as previously
reported [12].
Anti-luciferase siRNA (GL3) (target sequence 5′-CTT ACG CTG AGT
ACT TCG A-3′) was purchased from Dharmacon (Lafayette, CO) in
deprotected, desalted, annealed form. FAM-labeled siRNA (3′ end of
the sense strand) was used to evaluate the incorporation efﬁciency for
siRNA in the LPD. Cy3 labeled siRNA was used for the isolated liver
perfusion study.
NCI-H460 and CT26 cells were purchased from the American Type
Culture Collection, and TC-1 cells were obtained from Dr. T.C. Wu
(Johns Hopkins University, Baltimore, MD). Cells were cultured in
PRMI-1640 medium supplemented with 10% fetal bovine serum and
antibiotics.
2.2. Experimental animals
Female C57BL/6 mice of age 6–8 weeks (16–18 g) and female
athymic nude mice of age 6–8 weeks were purchased from Charles
River Laboratories (Wilmington, MA). All work performed with
animals was in accordance with and approved by the IACUC
committee at the University of North Carolina at Chapel Hill (UNC).llustration of the double lipid bilayer structure (B) and proposed mechanism for the
ssion [11].
Fig. 2. Stability of the nanoparticle formulations upon different degree of PEGylation. (A) Chemical structures of DOTAP and DSGLA. (B) Size distribution of different PEGylated
formulations. Data=mean±SD, n=4–6.
Fig. 3. TEM photographs of liposomes/PEGylated liposomes and LPD/PEGylated LPD.
Arrows indicate the “sprouts” of the particles and arrow heads indicate the small
particles. Bar=100 nm.
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LPD was prepared as previously described [8]. Brieﬂy, unmo-
diﬁed LPD was obtained by quickly mixing suspension A (8.3 mM
liposomes (DOTAP:cholesterol=1:1, molar ratio) and 0.2 mg/ml
protamine in 150 μl nuclease free water) with solution B
(0.16 mg/ml siRNA and 0.16 mg/ml calf thymus DNA in 150 μl
nuclease free water) followed by incubation at room temperature
for 10 min. PEGylated LPD was prepared by incubating the LPD
suspension (300 μl) with 37.8 μl micelle solution of DSPE-PEG2000
(10 mg/ml) at 50 °C for 10 min. PEGylated LPD was allowed to
stand at room temperature for 10 min. The charge ratio of the
formulation was about 1:5 (−:+). The particle size was measured
using a submicron particle sizer (NICOMP particle sizing systems,
AutodilutePAT Model 370, Santa Barbra, CA) in the NICOMP mode.
The zeta potential of various LPD formulations diluted in 1 mM
KCl was determined by using a Zeta Plus zeta potential analyzer
(Brookhaven Instruments Corporation, Holtsville, NY). PEGylated
LPD was freshly prepared and used within 20 min for the
following experiments. For size exclusion chromatography, either
10 mol% NBD-DOTAP labeled liposomes, 10 mol% DSPE-PEG2000-CF
labeled DSPE-PEG2000 or FAM-siRNA was used for the preparation
of the PEGylated LPD. For the liver perfusion study, cy3-siRNA was
used.
2.4. Negative-stain transmission electron microscopy
TEM images were acquired using a Phillips CM12 (FEI, Hillsboro,
OR). Brieﬂy, freshly prepared formulations (5 μl) were dropped
onto 300 mesh carbon-coated copper grids (Ted Pella, Inc.,
Redding, CA) and allowed a short incubation (5 min) at room
temperature. Grids were then stained with 1% uranyl acetate(40 μl) and wicked dry. All images were acquired at an accelerating
voltage of 100 kV. Gatan Digital Micrograph software was used to
analyze the images.
Fig. 4. Size exclusion chromatography of different samples. (A) Chromatography of neutral liposomes and pure DSPE-PEG2000; (B) chromatography of DOTAP in different
formulations; (C) chromatography of DSPE-PEG2000 in different formulations; (D) chromatography of different components in the PEGylated LPD. Data are representative
chromatography from 2 to 3 batches of formulations.
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Ten μl of the samples was loaded onto a PBS pre-equilibrated
SepharoseCL2Bcolumn(1×10cm).ThecolumnwaselutedwithPBSata
ﬂowratearound0.5ml/min.Elute fractions(200–300μl)werecollected,
diluted 1:1 in ethanol, and analyzed for ﬂuorescence intensity by using
a plate reader (λex: 485 nm, λem: 535 nm) (PLATE CHAMELEON
Multilabel Detection Platform, Bioscan Inc., Washington, DC).
2.6. Isolated liver perfusion study
C57BL/6micewere sacriﬁced and the interior vena cavawas incised
to allow the blood ﬂush out when 3 ml warm PBS was infused into the
mouse liver through the portal vein. cy3-siRNA containing LPD
formulations (300 μl) were incubated with 50 μl mouse serum at
37 °C for 10 min, and then diluted with PBS (ﬁnal volume=1ml). The
complex was infused into the isolated liver via the portal vein. Finally,
the liver was perfused with 3 ml warm PBS, excised, ﬁxed in 3.6%
paraformaldehyde in PBS for overnight, and frozen sectioned (5 μm in
thickness). Sections were washed with PBS, permeabilized with 0.1%
Triton X-100 in PBS, stained with Alexa Fluor® 488 Phalloidin
(Invitrogen, Eugene, OR), mounted with the DAPI containing medium
(Vectashield®, Vector Laboratories Inc., Burlingame, CA) and imaged
using a Leica SP2 confocal microscope.
2.7. Tissue distribution study
Tissue distribution of the FAM-labeled siRNA formulation in the
PEGylated LPD was analyzed 4 h after i.v. injection as previously
described [7].2.7. Statistical analysis
Data are presented as the mean±SD. The statistical signiﬁcance
was determined by using the analysis of variance (ANOVA, one way)
or the two-sided Student t-test. P values of b0.05 were considered to
be signiﬁcant.
3. Results and discussion
3.1. Characterization of the nanoparticles after PEGylation
PEG-phospholipids have been used widely in lipid based nano-
particle formulations, such as liposomes, to avoid the non-speciﬁc
uptake by RES and increase the circulation half-life [13]. It is also
known that incorporation of toomuch PEG-phospholipids will disrupt
the integrity of the lipid membrane due to its detergent-like
properties [14], which increases membrane permeability and pre-
mature drug release. Since the unmodiﬁed LPD contains two lipid
bilayer membranes, incubation with PEG-phospholipids may strip off
the membranes from the nanoparticles and form micelles of smaller
particle size. Here, we examined the stability of nanoparticle
formulations after the addition of different amounts of DSPE-
PEG2000 by measuring their particle size distribution. Two cationic
lipids, a monovalent lipid DOTAP and a trivalent lipid DSGLA (Fig. 2A),
were used in the study. By using DLS, only one narrow size
distribution around 100 nm was revealed for all four formulations
(polydispersity index b0.1), i.e., liposomes and LPD composed of
either DOTAP or DSGLA, before the addition of DSPE-PEG2000 (Fig. 2B).
However, after the addition of DSPE-PEG2000, a population of smaller
particles appeared in a dose dependent manner for both DOTAP and
Fig. 5. Tissue distribution analysis. (A) Liver sinusoidal uptake of cy3-siRNA in naked
LPD (positive control) and PEGylated LPD. Nuclei (blue), F-actin (green), cy3-siRNA
(red). Magniﬁcation=1600×. Data are representative pictures from 3 mice in each
group. (B) Fluorescence signal of FAM-labeled siRNA in different tissues detected by the
Xenogen IVIS imaging system. Data are from two representative animals in each group.
Data of the NCI-H460 model are reproduced from a previously published article with
permission [7].
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undetectable at the concentrations used in this experiment. Thus, the
smaller size particles must come off from the nanoparticles upon the
introduction of DSPE-PEG2000. The LPD formulations showed sig-
niﬁcantly higher stability compared to the liposomes. When 10 mol%
of DSPE-PEG2000 was added, the LPD formulations remained relativelystable, whereas the liposome formulations showed a signiﬁcant
increase in the population of small particles (∼5%). The DLS data
(Fig. 2B) is consistent with the observation by TEM (Fig. 3), in which a
mixture of disrupted particles and tubular micelles was found in the
DOTAP liposomes after PEGylation. On the other hand, intact
nanoparticles around 100 nm in diameter were still found in the
PEGylated LPD formulation containing DOTAP (Fig. 3). It is also
noticed that DSGLA (containing 3 positive charges)-LPD showed an
improved stability compared to DOTAP (containing 1 positive
charge)-LPD (Fig. 2B), suggesting that LPD was stabilized by charge–
charge interaction between the cationic lipid and the negatively
charged core. DLS was determined to be a convenient method to
assess the relative stability of the particles. For example, smaller size
particles were found in the TEM photographs of the PEGylated LPD
(Fig. 3, arrow heads); while DLS data showed no presence of smaller
particles (Fig. 2B). It is known that particles of larger sizes showed
signiﬁcant higher light scattering compared to smaller size particles at
the same concentration. Nevertheless, the dynamic light scattering
data provided a quantitative comparison of the relative stability of
different nanoparticle formulations.
As can be seen in Fig. 3, after 10 mol% PEGylation, DOTAP
liposomes were greatly disrupted andmost of themwere transformed
into tubular micellar structures, indicating the instability of the
formulation. In the PEGylated LPD, a mixture of particles around
10 nm (Fig. 3, arrow head), “sprouts” on the 100 nm-particles (Fig. 3,
arrows), and 100 nm-particleswas found, suggesting that the lipids on
the surface of the LPD (∼100 nm) were being stripped off (forming
sprouts) and eventually became smaller DSPE-PEG2000 containing
particles. The possibility of the presence of pure DSPE-PEG micelles in
the PEGylated LPD sample cannot be ruled out, since the DSPE-
PEG2000 micelles showed similar size (TEM data not shown) as the
smaller particles (Fig. 3, arrow head).
To further characterize the LPD nanoparticles, we studied in more
details the nanoparticle formulation containing DOTAP after incubat-
ing with 10 mol% DSPE-PEG2000. We have used either 10 mol% NBD-
DOTAP labeled liposomes, 10 mol% DSPE-PEG2000-carboxyﬂuorescein
(DSPE-PEG2000-CF) labeled DSPE-PEG2000 or FAM-siRNA to prepare
the PEGylated LPD. A Sepharose CL 2B column was used to separate
particles. In this study, a neutral liposome formulation (DOPC/
Cholesterol/NBD-PE=49/49/2, molar ratio, mean particle size
around 100 nm) was used to calibrate the column. Cationic liposomes
and unmodiﬁed LPD containing excess positive surface charges
formed aggregates in the elution medium (phosphate-buffered saline,
PBS) and thus, could not be studied by the chromatography. As shown
in Fig. 4A, pure DSPE-PEG2000 could be clearly separated from the
100 nm-nanoparticles by the size exclusion column chromatography.
At least two particle populations were observed in the NBD-DOTAP
labeled PEGylated LPD (Fig. 4B). The ﬁrst major peak coincided with
that of the 100 nm-nanoparticles, and the second peak appeared
between the peaks of micelles and 100 nm-nanoparticles. The
PEGylated liposomes (NBD-DOTAP labeled) showed less signiﬁcant
ﬁrst peak but a smear of particle size distribution, suggesting that the
lipid membrane was disrupted in this formulation. The observation is
consistent with DLS (Fig. 2B) and TEMdata (Fig. 3). Moreover, the area
under the curve (AUC) of the ﬁrst peak of the PEGylated LPD (NBD-
DOTAP labeled) was about 37.2% (37.2±4.6%, n=3). The data suggest
that approximately 37.2% of the total lipids were still associated with
the nanoparticles, while the rest of the lipids were stripped off by the
DSPE-PEG2000 and formed smaller particles (b100 nm). From the
cryo-TEM data (Fig. 2A), it can be calculated that approximately 36.4%
(36.4±3.2%, n=5) of the total lipids should be located in the inner
lipid bilayer of the LPD, suggesting that only the inner lipid bilayer
remained with the nanoparticles. The inner cationic lipid bilayer was
in direct contact with the negatively charged surface of the nucleic
acid/protamine core and therefore, could accommodate an increased
amount of DSPE-PEG2000 compared to the outer bilayer. It is noted that
Fig. 6. Proposed model for the formation of PEGylated LPD and the mechanism of favored tumor uptake.
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of the supported bilayer. Only 24.2% of the total cationic lipids
remained associated with the nanoparticles (data not shown),
indicating that substantial amount of the lipids in the supported
bilayer was removed in this high concentration of DSPE-PEG2000. Fig.
4C shows that around 20.6% (20.6±3.4%, n=3) of the input DSPE-
PEG2000 (DSPE-PEG2000-CF labeled) was incorporated with the
nanoparticles (ﬁrst peak) after incubation. Fig. 4D indicates that the
nanoparticles eluted in the ﬁrst peak contained 90% of siRNA, 37.2% of
the total lipids and 20.2% of the input DSPE-PEG2000. These
nanoparticles should be the major contributor for siRNA delivery for
the PEGylated LPD formulation.
Ten μl of the PEGylated LPD (loading amount for column)
contained 0.71 μg siRNA, 36.71 nmol lipids and 3.99 nmol DSPE-
PEG2000. The nanoparticles eluted in the ﬁrst peak contained 0.64 μg
siRNA, 13.66 nmol lipids and 0.81 nmol DSPE-PEG2000. Assuming
that DSPE-PEG2000 was inserted only into the outer leaﬂet of the
supported bilayer and the lipid content in the outer and inner leaﬂet
of the bilayer were the same, we calculated that 10.6 mol% of the
outer leaﬂet was modiﬁed with DSPE-PEG2000. This led to a
complete charge shielding. The zeta potential of the unmodiﬁed
LPD was about 40 mV, but the puriﬁed PEGylated LPD was −5.6
±4.5 mV. Approximately 90% siRNA was encapsulated in the
puriﬁed PEGylated LPD, which was a neutral delivery vehicle that
is desirable for in vivo drug delivery because of its improved
pharmacokinetics and reduced non-speciﬁc interaction with cells or
serum protein.
Depending on the surface density andmolecular weight of the PEG
grafted to the lipid bilayer, three PEG conformations can be identiﬁed
[15]. Factors controlling the PEG conformation include the distance
between the PEG chains in the lipid bilayer (D) and the Flory
dimension, RF, which is deﬁned as aN3/5 (a is the persistence length of
the monomer, N is the number of monomer units in the PEG) [16].
Three regimes can be deﬁned: (a) when DN2 RF (interdigitated
mushrooms); (b) when Db2 RF (mushrooms); and (c) when DbRF
(brushes) [16]. For a 100 nm-liposomal particle grafted with DSPE-
PEG2000, PEG chains should be arranged in the mushroommode in the
presence of b4 mol% DSPE-PEG2000; in the transition mode with a 4–
8 mol% modiﬁcation; and in the brush modewith N8 mol% PEGylation[17]. The brush conﬁguration ensures that the entire surface of
nanoparticles is covered [18] and provides the nanoparticles with full
protection from opsonization. It is difﬁcult to prepare stable PEGylated
liposomes with the brush conformation of PEG while maintaining the
integrity of lipid membrane.When PEG is arranged in the brushmode,
the repulsion force among PEGs may cause disruption of the lipid
bilayer, as what have been shown in this study. On the other hand, the
LPD nanoparticles contained two lipid bilayers; the regular outer layer
was stripped off by the DSPE-PEG2000, while the supported bilayer
that was stabilized by charge–charge interaction remained intact after
accommodated 10.6 mol% DSPE-PEG2000 with the PEG arranged in the
brush conformation.
Applying another force to antagonize the repulsion among the
PEGs; i.e., charge–charge interaction from the supported bilayer of
LPD, is the key to maintain a high mol% of PEG arranged in the
brush mode. Hu and Wu reported another method to prepare highly
PEGylated particles with PEG in the brush conﬁguration [19,20].
They synthesized a thermally sensitive polymer (PNIPAM (poly[N-
isopropylacrylamide]) grafted with linear PEG chains) that self-
assembled into microgel at 25 °C, followed by increasing the
temperature to ∼35 °C, which shrank the particle size by 3-fold and
reduced the surface area by 10-fold and thus the PEGs were forced
to settle in the brush mode. In this case, the force from the
hydrophobic interaction between the polymers stabilized the PEG
conformation [20].
3.2. Uptake of the LPD nanoparticles in the isolated liver and the tissue
distribution after i.v. administration
To further investigate if the PEGylated LPD showed low RES
uptake in the mouse liver, we performed a liver perfusion assay. Cy3
labeled siRNA was formulated in the PEGylated LPD containing
DOTAP and mixed with the mouse serum for 10 min before infused
into the liver. After the infusion, the liver was perfused with warm
PBS and excised, ﬁxed, sectioned, and examined by confocal
microscopy. As shown in Fig. 5A, the nuclei of the liver tissue
were stained as blue, the F-actin outlining the cell morphology was
stained with Alexa Fluor® 488 Phalloidin as green, and the siRNA
was labeled with cy3 and shown as red. Thus, the sinus where the
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distinct morphologies as indicated by the arrow (hepatocyte) and
arrow head (sinus). The PEGylated LPD showed little sinusoidal
uptake in the liver, while the positive control, unmodiﬁed LPD that
has been demonstrated to accumulate in the RES [5], displayed
intense liver sinusoidal uptake. The data indicate that the PEG on
the LPD surface arranged in the brush mode prevented serum
opsonization and abolished the non-speciﬁc RES uptake in the
isolated liver. Since the RES uptake in the liver and spleen often
contributes to the major loss of injected nanoparticles, the data also
suggest that the fully protected LPD of low RES uptake might have
an improved chance to reach the tumor via the enhanced
permeability and retention (EPR) effect [21].
Then, we examined the tissue distribution of FAM-labeled siRNA
formulated in PBS or in the PEGylated LPD containing DOTAP in 3
different tumor models (NCI-H460 in nude mice, TC-1 in C57BL/6
mice, and CT26 in Balb/c mice). Four hours after the i.v. injection,
we euthanized the mice, collected tissues and used the Xenogen
IVIS imaging system to examine the FAM-siRNA signals. As can be
seen in Fig. 5B, free FAM-siRNA exhibited little bioavailability for the
major tissues from all 3 models except the liver of the C57BL/6
mice. PEGylated LPD, however, showed very high delivery efﬁciency
for FAM-siRNA to the tumors, while leaving other normal tissues
with minimal to moderate uptake, particularly in the NCI-H460
model. We have also extracted the accumulated FAM-siRNA from
the tissues in the NCI-H460 model and measured the amount of the
ﬂuorescent siRNA. The accumulated doses of free FAM-siRNA were
5.0±2.2% injected dose (ID) in the tumor, 0.8±1.4% in the heart,
1.5±0.5% in the lung, 0.8±1.6% in the kidney and 21.8±5.1% in the
liver, respectively (data=mean±SD, n=3–4). PEGylated LPD
delivered 32.5±11.3% ID to the tumor, 3.9±2.1% to the lung and
12.0±5.7% to the liver, respectively, while the levels of FAM-siRNA
were under the detection limit in the rest of the tissues
(data=mean±SD, n=3–4). The data showed that the PEGylated
LPD displayed efﬁcient delivery of siRNA to the tumor with low
uptake by the RES in the liver and the spleen. The tumor uptake,
which greatly exceeded the liver uptake, had become the major
clearance mechanism of the nanoparticles from the circulation [7].
Tumor uptake occurred very early after i.v. administration. In fact,
when the tissues were examined 0.5 h after injection of the
PEGylated LPD, 13.8±2.3% ID was already accumulated in the
tumor, leaving the liver with only 4.0±2.3% and the spleen with 1.3
±0.3% (data=mean±SD, n=4). The initial low uptake by the RES
was likely due to the low level of opsonization of the PEGylated LPD
resulting from the PEG brush on the particle surface. It should be
noted that the neovasculature of the tumor is signiﬁcantly leakier
than that of the liver sinusoidal membrane [22,23] which provides a
signiﬁcant opportunity for the nanoparticles to extravasate into the
tumor. In the tumor free animals, the nanoparticles circulated for a
longer period of time, but were still eventually taken up by the liver
just as all “stealth liposomes” [7].
3.3. Proposed model for the formation of PEGylated LPD nanoparticles
and the mechanism of avoiding RES uptake
After the addition of DSPE-PEG2000 micelles at 50 °C, the micelles
act like detergents and strip off the outer lipid bilayer of the LPD
(Fig. 6). In the intermediate phase, “sprouts” (outer bilayer being
stripped off from the LPD) are formed and eventually are broken
down into smaller PEGylated lipid particles. The inner lipid bilayer
is stabilized by charge–charge interaction and therefore, remains
intact. A brush layer of PEG is present on the surface of the
nanoparticles due to the insertion of a large amount of DSPE-
PEG2000, which completely shields the surface charge of the
unmodiﬁed LPD. The well protected nanoparticles with presumably
reduced opsonization can thus avoid the initial clearance by the RESand are favored for penetration into the tumor through its leaky
neovasculature. We have thus demonstrated the role of the
supported bilayer in improving the in vivo stability and tumor
delivery of the PEGylated LPD.
4. Conclusion
Using a variety of analytical techniques, we have demonstrated
that the LPD nanoparticles contained two lipid bilayers with the inner
bilayer stabilized by charge–charge interaction. During the process of
post-insertion of PEGylated lipids, the regular outer bilayer was
stripped off from the particles due to the detergent-like effect and the
PEGylated lipids were incorporated into the outer layer of the
supported bilayer with increased stability, which accommodated up
to 10.6 mol% of DSPE-PEG. The highly PEGylated nanoparticles with
the PEG arranged in the brush mode displayed neutral surface charge
and minimal protein binding when mixed with serum, resulting in
little RES uptake; and thus showed high tumor accumulation. Here,
we have shown the importance of incorporating a stabilizing
mechanism (i.e. supported bilayer) in a nanoparticle formulation
that allows an increased level of PEGylation to further decrease the
opsonization effect and RES uptake, leading to much improved tumor
delivery.
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